<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B63AE49-2D9C-4780-B113-B0805A2E1EAC"><gtr:id>4B63AE49-2D9C-4780-B113-B0805A2E1EAC</gtr:id><gtr:name>Institute for Research in Biomedicine (S</gtr:name><gtr:address><gtr:line1>Institute for Research in Biomedicine</gtr:line1><gtr:line2>Via Vela 6</gtr:line2><gtr:postCode>CH 6500</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F1AA9E37-A42D-4929-9C6D-583BF2C93F1F"><gtr:id>F1AA9E37-A42D-4929-9C6D-583BF2C93F1F</gtr:id><gtr:name>University of South Australia</gtr:name><gtr:address><gtr:line1>Frome Rd</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FDA2749-D31C-4822-8F9A-0CF364CA651D"><gtr:id>8FDA2749-D31C-4822-8F9A-0CF364CA651D</gtr:id><gtr:name>ExSAR Corporation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E06F3D8-F95A-47ED-8F46-70973932D352"><gtr:id>1E06F3D8-F95A-47ED-8F46-70973932D352</gtr:id><gtr:name>Palacky University</gtr:name><gtr:address><gtr:line1>Palacky University</gtr:line1><gtr:line2>Krizkovskeho 8</gtr:line2><gtr:postCode>CR 771 47</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Northern Institute for Cancer Research</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B63AE49-2D9C-4780-B113-B0805A2E1EAC"><gtr:id>4B63AE49-2D9C-4780-B113-B0805A2E1EAC</gtr:id><gtr:name>Institute for Research in Biomedicine (S</gtr:name><gtr:address><gtr:line1>Institute for Research in Biomedicine</gtr:line1><gtr:line2>Via Vela 6</gtr:line2><gtr:postCode>CH 6500</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F1AA9E37-A42D-4929-9C6D-583BF2C93F1F"><gtr:id>F1AA9E37-A42D-4929-9C6D-583BF2C93F1F</gtr:id><gtr:name>University of South Australia</gtr:name><gtr:address><gtr:line1>Frome Rd</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FDA2749-D31C-4822-8F9A-0CF364CA651D"><gtr:id>8FDA2749-D31C-4822-8F9A-0CF364CA651D</gtr:id><gtr:name>ExSAR Corporation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E06F3D8-F95A-47ED-8F46-70973932D352"><gtr:id>1E06F3D8-F95A-47ED-8F46-70973932D352</gtr:id><gtr:name>Palacky University</gtr:name><gtr:address><gtr:line1>Palacky University</gtr:line1><gtr:line2>Krizkovskeho 8</gtr:line2><gtr:postCode>CR 771 47</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/836A9506-D05E-47ED-B9F0-7E1F04958C4C"><gtr:id>836A9506-D05E-47ED-B9F0-7E1F04958C4C</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Endicott</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901526"><gtr:id>F4C58F0A-C2DA-4D05-A0FE-5EE9E6F63FFB</gtr:id><gtr:title>CDK-containing macromolecular assemblies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901526</gtr:grantReference><gtr:abstractText>The growth and division of cells is strictly controlled at the molecular level by a number of enzymes that include the cyclin dependent protein kinases (CDKs). CDKs 1, 2, 4 and 6 are switched on and off in an orderly sequence, to ensure that cell division starts and stops at the required time. Other members of the CDK family (CDKs 7, 8 and 9) are also important for the control of transcription, the process by which genes are transcribed into messenger RNA that in turn serves as the template for protein synthesis. Regulation of transcription ensures the timely expression of proteins required for cell growth and differentiation. Errors in either the control of cell cycle progression or transcription can lead to uncontrolled cell growth and proliferation. Although CDK family members are closely related in sequence, biological studies have revealed that each has unique properties. Their activities can be regulated both by association with different families of regulatory proteins and by enzymatic modification of the protein sequence by addition of phosphoryl or acetyl residues to specific amino acid side chains. Our work, primarily using the technique of X-ray crystallography, allows us to see the structures of CDKs and the complexes they form at atomic resolution and so to learn how they differ from each other. The aim of this proposal is to build upon our research into the structural and functional properties of CDK/cyclin pairs, to establish how structural and biochemical properties are altered when they are located in multi-protein complexes. To this end we propose to identify and reconstitute selected CDK-containing complexes using heterologous expression systems. We will characterise these complexes by structural, biochemical, and biophysical methods. Aberrant CDK activity has been linked to cancer, neurological diseases, and rheumatoid arthritis In recent years, understanding a particular defect that leads to disease has led to exciting new medicines directed towards a particular target (e.g. the drugs Gleevec, Iressa and Herceptin for cancer treatment). A number of CDK-selective inhibitors are in clinical trials for the treatment of cancer. These agents all act by binding to the CDK active site to block CDK activity. Compounds that block other interactions made by CDK/cyclin complexes represent an alternative target for CDK-directed therapies. The work described in this project will aid the further development of such compounds and may also reveal additional targets for inhibitor development.</gtr:abstractText><gtr:technicalSummary>Cyclin-dependent protein kinases (CDKs) play an orchestrating role in cellular processes that include transcriptional regulation and the control of cell-cycle progression. Aberrant CDK activity is implicated in diverse clinical conditions including cancer, stroke, neurodegeneration and HIV infection. Whereas CDKs isolated ex vivo are found in large, multi-protein complexes, the prevailing understanding of the CDK structure-function relationship has largely been deduced from the study of variously phosphorylated monomeric or cyclin-bound CDKs. We aim to extend available understanding of the composition, structure and functional properties of the multiprotein complexes that characterise the different CDKs. In particular we will develop a structural view of the complexes that localise and regulate CDK7 and CDK9 activity in transcriptional control, selected complexes that contain CDK4 and CDK6 and coordinate cell-cycle progression with checkpoint and apoptotic pathways, and complexes of CDKs 1 and 2 that coordinate their activity with the ubiquitin-proteolysis system.</gtr:technicalSummary><gtr:fund><gtr:end>2016-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3294267</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Northern Institute for Cancer Research Newcastle</gtr:department><gtr:description>CDK4/6-Androgen Receptor</gtr:description><gtr:id>94B3CC3E-7D1B-4ACD-BE22-0661945400D4</gtr:id><gtr:impact>No publications as of 11/2015. Results of collaborative experiments were included in a subsequent application to the MRC for programme grant funding.</gtr:impact><gtr:outcomeId>UvhK1cv9jjA-1</gtr:outcomeId><gtr:partnerContribution>Provision of appropriate cell lines and expertise for cell-based studies of androgen receptor function (transfection, si RNA, ChIP and lenti-viral-mediated knockdown),</gtr:partnerContribution><gtr:piContribution>Provision of CDK and cyclin constructs and protein for in vitro and cell-based studies to elucidate CDK-androgen receptor interactions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astex Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CDK2 inhibitor studies</gtr:description><gtr:id>4806EF7E-7FDF-445C-B7D7-1B1F01CCBCC5</gtr:id><gtr:impact>CDK2/cyclin A/inhibitor complexes
Multidisciplinary: small molecule chemical synthesis, biochemical and cellular assays, X-ray crystallography, drug design</gtr:impact><gtr:outcomeId>smxE9MuuYsi-2</gtr:outcomeId><gtr:partnerContribution>Provision of proprietary CDK inhibitors and cell-based assay protocols and reagents</gtr:partnerContribution><gtr:piContribution>Provision of CDK/cyclin complexes for structure determination by X-ray crystallography</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ExSAR Corporation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Analysis of CDK9/cyclin T complexes by mass spectrometry</gtr:description><gtr:id>0429E014-3BC8-45BA-9F8B-4C31E21EB13E</gtr:id><gtr:impact>Determination of molecular model for both the CDK9/cyclin T/BRD4 and /HEXIM1 complexes. Manuscript in preparation.
Multidisciplinary: Mass spectrometry, X-ray crystallography, NMR</gtr:impact><gtr:outcomeId>nGkKZsGZ5xe-1</gtr:outcomeId><gtr:partnerContribution>Access to equipment, significant intellectual input and experimental expertise.</gtr:partnerContribution><gtr:piContribution>Provision of CDK9/cyclin T/BRD4 and /HEXIM1 protein complexes of sufficient purity for H/D exchange analysis.
Initial complex characterisation by X-ray crystallography and NMR.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Palacky University</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>Determination of structures of CDK9/cyclin T ATP-competitive inhibitors.</gtr:description><gtr:id>36FE2FB4-BDFC-4D1D-BD78-1035C3B9C6FC</gtr:id><gtr:impact>Structure determination of CDK9/cyclin T/inhibitor complex structures. One joint review published: 
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
Krystof V, Baumli S, F&amp;uuml;rst R.
Curr Pharm Des. 2012;18(20):2883-90. Review.</gtr:impact><gtr:outcomeId>D109BCAD167-1</gtr:outcomeId><gtr:partnerContribution>Provision of small molecule inhibitors for co-crystallisation studies to 1) improve structure resolution and 2) as part of a structure-aided inhibitor design program. Complementary biochemical and cellular characterisation of inhibitors.</gtr:partnerContribution><gtr:piContribution>Determination of structures of CDK9/cyclin T/ATP-competitive inhibitor complexes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Institute for Cancer Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Branch</gtr:department><gtr:description>Structure/function studies of CDK and CDK regulatory protein complexes</gtr:description><gtr:id>D7459439-B89B-4A4F-89C4-3E4CDF6BBB07</gtr:id><gtr:impact>Two manuscripts published:
(1) Lu, M., Breyssens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Sullivan, A., Brown, N.R., Endicott, J.A., Knapp, S., Kessler, B., Middleton, M.R., Siebold, C., Jones, Y., Sviderskaya, E.V., Cebon, J., John, T., Goding, C.T. and Lu, X. (2013) Restoring p53 function in human melanoma cells by inhibiting mdm2 and cyclinB1/cdk1 phosphorylated nuclear iASPP. Cancer Cell, 23:618-33. 
(2) Lu, M., Zak, J., Chen, S., Sanchez-Pulido, L., Severson, D.T., Endicott, J., Ponting, C.P., Schofield, C.J., and Lu, X. (2014) A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway. Cell 157:1130-450. 
Collaboration is multidisciplinary: cell culture, FACS and imaging at Oxford, biochemical, biophysical and structural characterisation of CDK-containing complexes at Newcastle.</gtr:impact><gtr:outcomeId>hcB7fDqAeqv-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise in cellular studies and cell imaging for functional studies.</gtr:partnerContribution><gtr:piContribution>Generation of constructs for cellular studies, proteins and supporting biochemical, biophysical and structural characterization</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Genome Damage and Stability Centre</gtr:department><gtr:description>CDC37/HSP90/CDK complexes</gtr:description><gtr:id>9F726EFD-945E-4B24-B46D-A33D95122846</gtr:id><gtr:impact>Joint manuscript submitted as of 12/2015.</gtr:impact><gtr:outcomeId>Csq7n3aD8oX-1</gtr:outcomeId><gtr:partnerContribution>Provision of CDC37 and HSP90 proteins, biochemical, biophysical and structural characterisation of CDK/CDC37 and CDK/CDC37/HSP90 complexes</gtr:partnerContribution><gtr:piContribution>Provision of CDK4/6 complexes, biochemical, biophysical and structural characterisation of CDK/CDC37 and CDK/CDC37/HSP90 complexes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of South Australia</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>CDK inhibitors</gtr:description><gtr:id>1ECAA384-C136-4A09-8CF0-0BB3B00D580C</gtr:id><gtr:impact>Multidisciplinary. Chemical syntheses and assay at University of South Australia, protein structure determination by X-ray crystallography at Newcastle University. Two papers published to date when collaborator was working at the University of Nottingham.</gtr:impact><gtr:outcomeId>56d9a178742229.14935553-1</gtr:outcomeId><gtr:partnerContribution>Provision of potent and selective CDK ATP-competitive inhibitors.</gtr:partnerContribution><gtr:piContribution>Provision of CDK-cyclin complexes for structure determination bound to ATP-competitive inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astex Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Astex Therapeutics Ltd</gtr:department><gtr:description>CDK1/cyclin B/inhibitor complexes</gtr:description><gtr:id>21E4CD8B-86FB-4B19-8F1F-7E79141AE5ED</gtr:id><gtr:impact>None as of 11/2015</gtr:impact><gtr:outcomeId>D3hdoXU4v11-1</gtr:outcomeId><gtr:partnerContribution>Provision of proprietary CDK1/cyclin B-selective inhibitors</gtr:partnerContribution><gtr:piContribution>Provision of CDK1/cyclin B protein for structure determination.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CDK2 inhibitor studies</gtr:description><gtr:id>06153944-F243-47DF-AB83-C3A5C104554D</gtr:id><gtr:impact>CDK2/cyclin A/inhibitor complexes
Multidisciplinary: small molecule chemical synthesis, biochemical and cellular assays, X-ray crystallography, drug design</gtr:impact><gtr:outcomeId>smxE9MuuYsi-3</gtr:outcomeId><gtr:partnerContribution>Provision of proprietary CDK inhibitors and cell-based assay protocols and reagents</gtr:partnerContribution><gtr:piContribution>Provision of CDK/cyclin complexes for structure determination by X-ray crystallography</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Biological Station, Roscoff</gtr:department><gtr:description>Structural and functional characterisation of CDK9/cyclin T ATP-competitive inhibitors</gtr:description><gtr:id>37F8FD3A-71DA-44A4-97D0-2420A09BD7A9</gtr:id><gtr:impact>Structure determination of CDK9/cyclin T/inhibitor complex structures. Manuscript now published (Genes and Cancer, 2010). Multidisciplinary collaboration involving compound synthesis, cellular assays, and X-ray crystallography.</gtr:impact><gtr:outcomeId>C451133DB2F-1</gtr:outcomeId><gtr:partnerContribution>Provision of small molecule inhibitors for co-crystallisation studies to 1) improve structure resolution and 2) as part of a structure-aided inhibitor design program. Complementary biochemical and cellular characterisation of inhibitors.</gtr:partnerContribution><gtr:piContribution>Determination of structures of CDK9/cyclin T/ATP-competitive inhibitor complexes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Biological Chemistry &amp; Molecular Pharmacology (BCMP)</gtr:department><gtr:description>CDK7 ATP-competitive inhibitors</gtr:description><gtr:id>AD474BAB-4437-4F60-B687-968108F44110</gtr:id><gtr:impact>As yet no outputs, CDK7 still in crystallisation trials. Multi-disciplinary structure/function study to identify leads for anti-cancer drug design. X-ray crystallography, chemical synthesis, in vitro biochemical and cell-based assays.</gtr:impact><gtr:outcomeId>W9brqeecsk5-1</gtr:outcomeId><gtr:partnerContribution>In vitro and in vivo functional characterisation of inhibitors as leads for drug design.</gtr:partnerContribution><gtr:piContribution>Co-crystallisation of CDK7 with ATP-competitive inhibitors for structural studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>CDK PTMs</gtr:description><gtr:id>A5DAE0B3-B3C8-49E6-A9C9-D9D2F77A2646</gtr:id><gtr:impact>Exchange of reagents.</gtr:impact><gtr:outcomeId>56d85a66545fe4.47321263-1</gtr:outcomeId><gtr:partnerContribution>Identification of novel post-translational modifications on CDKs. Characterisation by mass spectrometry</gtr:partnerContribution><gtr:piContribution>Generation of CDK1- and CDK2-cyclin complexes.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy</gtr:department><gtr:description>Determination of CDK9/cyclin T/ATP-competitive inhibitor structures</gtr:description><gtr:id>AFDF3763-1EAD-488D-A365-ECB36121DC13</gtr:id><gtr:impact>Multidisciplinary: inhibitor synthesis and in vitro assays at Nottingham, structural characterisation started at Oxford. Activity now transferred to NICR, Newcastle University. 
Two papers published:
1. Shao,H., Shi,S., Huang, S., Hole, A.J., Abbas, A.Y., Baumli, S., Liu,X., Lam, F., Foely, D., Fischer, P.M., Noble, M.E.M., Endicott, J.A., Pepper, C. and Wang, S. (2013) Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, x-ray crystal structure, SAR and anti-cancer activities. J.Med. Chem. 56:640-59.

2. Hole, A.J., Baumli, S., Shao, H., Shi, S., Huang, S., Abbas, A.Y., Liu, X., Lam, F., Pepper, C., Fischer, P.F., Wang, S., Endicott, J.A. and Noble, M.E.M. (2013) Comparative binding of 2-amino-4-heteroaryl-pyrimidine inhibitors to CDK2 and CDK9. J.Med. Chem. 56:660-70.

3. Successful application for further funding: CRUK Science Committee - Drug Discovery Project Award (PI P. Fischer, Nottingham University, Award ref: C18648/A17648)</gtr:impact><gtr:outcomeId>W2jvMW2d8mk-1</gtr:outcomeId><gtr:partnerContribution>Provision of CDK9-specific inhibitors for co-crystallisation studies for structure lead inhibitor design. Hold a CRUK DDERP award (01/01/14-31/12/15) on which we are a collaborator and receive &amp;pound;5000/annum towards consumables.</gtr:partnerContribution><gtr:piContribution>Provision of CDK9/cyclin T for structure determination of inhibitor complexes by X-ray crystallography</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>EM structure determination of P-TEFb complexes</gtr:description><gtr:id>99F6E1E5-C1F5-4907-89B2-B8292F06353B</gtr:id><gtr:impact>With advice from partners, successful generation of samples suitable for data collection. Structure determination in progress.</gtr:impact><gtr:outcomeId>56d8579554b1e0.41427717-1</gtr:outcomeId><gtr:partnerContribution>Expertise in EM data collection and analysis of protein-RNA complexes. Access to a Titan Krios microscope.</gtr:partnerContribution><gtr:piContribution>Preparation of samples for EM analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Research in Biomedicine (IRB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>CDK1 and CDK2 complexes with RINGO/Speedy regulators</gtr:description><gtr:id>8A970D6D-D324-4A62-B06E-D6BB16196D1F</gtr:id><gtr:impact>Collaborator provided data that assisted in the preparation of an application to the MRC for programme grant support.</gtr:impact><gtr:outcomeId>56d85963e1ef64.41647490-1</gtr:outcomeId><gtr:partnerContribution>Biochemical characterisation of RINGO/Speedy proteins. Provision of unpublished results relating to RINGO/Speedy protein expression and characterisation. Provision of cDNAs, mutants and other RINGO/Speedy reagents. Mouse models to interrogate the functions of RINGO/Speedy in vivo</gtr:partnerContribution><gtr:piContribution>Preparation of CDK1 and CDK2 proteins together with various regulators. Biochemical and structural characterisation of CDK-containing complexes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Northern Institute for Cancer Research Newcastle</gtr:department><gtr:description>Cellular studies of CDK4</gtr:description><gtr:id>38799012-4709-4CBC-A23F-9F0972609713</gtr:id><gtr:impact>Generation of stable transfected cell lines for further functional characterisation. Collaboration is multidisciplinary: cell culture, FACS and imaging at NICR, biochemical, biophysical and structural characterisation of CDK4-containing complexes at Newcastle.</gtr:impact><gtr:outcomeId>rvKqAKJbfzS-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise in cellular studies and cell imaging</gtr:partnerContribution><gtr:piContribution>Generation of constructs for cellular studies and supporting biochemical, biophysical and structural characterisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>CDK2 inhibitor studies</gtr:description><gtr:id>BEC0FCF4-53A1-45D2-B4F4-9CAE4234751B</gtr:id><gtr:impact>CDK2/cyclin A/inhibitor complexes
Multidisciplinary: small molecule chemical synthesis, biochemical and cellular assays, X-ray crystallography, drug design</gtr:impact><gtr:outcomeId>smxE9MuuYsi-1</gtr:outcomeId><gtr:partnerContribution>Provision of proprietary CDK inhibitors and cell-based assay protocols and reagents</gtr:partnerContribution><gtr:piContribution>Provision of CDK/cyclin complexes for structure determination by X-ray crystallography</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit (Newcastle)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CAB20E44-74BE-4E2A-926E-B2ACF6A34ABF</gtr:id><gtr:impact>Visit to a class of 20 year 1 children to introduce them to doing experiments and analysing the results- chromatography of inks and discussion of life being a scientist as examples.</gtr:impact><gtr:outcomeId>56d98e3c1e92e0.32878118</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department Open Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF29056D-E4DA-4E9B-9182-2A719433B799</gtr:id><gtr:impact>Open Day posters describing the group's research. Tour of the facilities. Open Day well attended by sixth form students looking to study at Oxford.

An opportunity to inform sixth form science teachers that we welcome students for work experience placements.</gtr:impact><gtr:outcomeId>iZrHJVndXTy</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Workshop (Newcastle)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>386F66B9-8FDB-433D-8A69-DB8A88C56164</gtr:id><gtr:impact>6 x 2hour sessions each attended by between 12-24 year12-13 students which got them to think about serendipity in drug design and asked them to use molecular graphics to design a drug to overcome a drug-resistant target (British Science week Newcastle, 2013). Engagement in British Science week event (Durham, 2016).

Part of an ongoing program of outreach coordinated by members of staff at the Northern Institute for Cancer Research to the local community. Impact monitored by locally based CRUK Outreach Officer.</gtr:impact><gtr:outcomeId>bNAnSmvfW4n</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Race for Life (Newcastle)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>83A71EA8-CA65-4054-AD4A-530118F1F49F</gtr:id><gtr:impact>Public engagement in cancer research. Short talk and thank you to women running a &amp;quot;Race for Life&amp;quot;.

Highlights the work of the Institute - interested groups ask for building tours and to meet scientists.</gtr:impact><gtr:outcomeId>s6XVpvdRoPp</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2014,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4D5DC7BA-F96C-4F94-938F-23F193E4464E</gtr:id><gtr:impact>Engaging biology and chemistry students at a local school to think about where cancer medicines have come from and will come from in the future. Students had lots of questions and particularly enjoyed the interactive graphics.

Visits such as these have encouraged pupils in year 12 to approach us for a work experience/short summer placement in the lab</gtr:impact><gtr:outcomeId>545a94293356e9.95083989</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DDERP Discovery Award</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>77E731F6-0054-4AA2-8843-BE7224A7D84A</gtr:id><gtr:outcomeId>kwudZVRiUrQ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2290641</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Responsive Mode</gtr:description><gtr:end>2021-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N009738/1</gtr:fundingRef><gtr:id>3EB9A51C-2515-48C1-83C0-17510A8874F2</gtr:id><gtr:outcomeId>56d85c63319da5.62436389</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125828</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JGW Patterson Foundation</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>6D98E54D-9782-4709-866B-396CB19157CA</gtr:id><gtr:outcomeId>56d8603dc1e951.34333848</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>9A6F335D-4193-48F9-B85A-76383A1EC145</gtr:id><gtr:outcomeId>j1D9Nj25kpr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4B7553C8-FC08-47E6-AF03-4BD6855A6C9C</gtr:id><gtr:outcomeId>EMe5iWEjaSM</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Crystals of CDK2/cyclin A suitable for small molecule inhibitor soaks/co-crystallisation</gtr:description><gtr:id>A9FCF5A1-1210-4092-A8B5-5D426E332AC0</gtr:id><gtr:impact>Large number of CDK2/cyclin A/ATP-competitive inhibitor structures determined that have had an impact on the development of protein kianse inhibitors</gtr:impact><gtr:outcomeId>545a95f4907448.09828357</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CDK2/cyclin A crystals</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>CDK1-cyclin B suitable for assay and crystallisation.</gtr:description><gtr:id>BE742EDA-BF69-40FF-A7F6-5C782572B4AD</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:outcomeId>56d864a7eddb01.48346344</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CDK1-cyclin B crystals</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Crystals of CDK9/cyclin T suitable for use in determining binding modes of ATP-competitive inhibitors. Information is useful for the structure-aided design of selective CDK9 inhibitors in academia / pharmaceutical industry.</gtr:description><gtr:id>C199549C-0EC4-4FAE-9989-1BAB8EB35A91</gtr:id><gtr:impact>Structure determination of CDK9/cyclin T/inhibitor complex structures.</gtr:impact><gtr:outcomeId>AEF6813AA39</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CDK9/cyclin T crystals</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4319DCFB-652B-410B-B313-52D1D305F75F</gtr:id><gtr:title>An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fed83e90bf8d87dc8d03c7940fc46e4"><gtr:id>2fed83e90bf8d87dc8d03c7940fc46e4</gtr:id><gtr:otherNames>Echalier A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>545a328481bc83.59122900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C573FE7C-2615-4ADA-8A81-33FC3533CE05</gtr:id><gtr:title>The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f8e48a2e79aa7248cba2f4f3f00586"><gtr:id>79f8e48a2e79aa7248cba2f4f3f00586</gtr:id><gtr:otherNames>Baumli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>pm_14666_26_22292676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15220402-1518-4F2F-9456-0BD8F2857520</gtr:id><gtr:title>Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b9123febd8c6ea415075cd97647a5a"><gtr:id>b9b9123febd8c6ea415075cd97647a5a</gtr:id><gtr:otherNames>Hallett ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9ec3f1080050.95891425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B9BCD90-BBCD-4991-B72E-49C94AB0C2D9</gtr:id><gtr:title>Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e023955a5f4663f8ce1f592b9242603e"><gtr:id>e023955a5f4663f8ce1f592b9242603e</gtr:id><gtr:otherNames>Whittaker SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>5a995f814b0295.37691998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40BA43D6-D808-47C4-A8D8-8DF5AD95E697</gtr:id><gtr:title>CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cc8aa5474da27ea8392e2321066819c"><gtr:id>0cc8aa5474da27ea8392e2321066819c</gtr:id><gtr:otherNames>Brown NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c28b9344c153.08220867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3333E3DF-CBC0-4E4E-AF85-EEBF6E38D384</gtr:id><gtr:title>Herpes Simplex Virus 1 (HSV-1) ICP22 protein directly interacts with cyclin-dependent kinase (CDK)9 to inhibit RNA polymerase II transcription elongation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/902c64ce38331eba7823e490547bc157"><gtr:id>902c64ce38331eba7823e490547bc157</gtr:id><gtr:otherNames>Zaborowska J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460b43b0009c6.37536939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AB6C965-C3BE-499E-A305-F5425C25F1EE</gtr:id><gtr:title>Structural characterization of the cyclin-dependent protein kinase family.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a64145c472aa10129ba57d007a79ffb1"><gtr:id>a64145c472aa10129ba57d007a79ffb1</gtr:id><gtr:otherNames>Endicott JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_14666_26_23863171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61506E70-3528-431B-91F6-283331064CAA</gtr:id><gtr:title>Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c3b9c02800c86c026505b940f8da308"><gtr:id>7c3b9c02800c86c026505b940f8da308</gtr:id><gtr:otherNames>Coxon CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>58c28ca1921b34.77788410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BDD6775-0A7A-4767-93CB-1771F4E14076</gtr:id><gtr:title>Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3d05a74a9c24075abea5ad74e5560e8"><gtr:id>f3d05a74a9c24075abea5ad74e5560e8</gtr:id><gtr:otherNames>Shao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14666_26_23301767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B124AAE-AF82-4137-8FFF-C6A9F4F87424</gtr:id><gtr:title>A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f608465622159d0552333bad2a2893"><gtr:id>79f608465622159d0552333bad2a2893</gtr:id><gtr:otherNames>Lu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>545a33474cf683.51611005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAD06A6C-BC09-4C95-A5CB-FD70F0EA9261</gtr:id><gtr:title>The structural basis for control of eukaryotic protein kinases.</gtr:title><gtr:parentPublicationTitle>Annual review of biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a64145c472aa10129ba57d007a79ffb1"><gtr:id>a64145c472aa10129ba57d007a79ffb1</gtr:id><gtr:otherNames>Endicott JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4154</gtr:issn><gtr:outcomeId>pm_14666_26_22482904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAAA1257-967F-4133-823D-3B5E47BB7543</gtr:id><gtr:title>Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24e96fc4a7147a7cd5923d7a4057e39b"><gtr:id>24e96fc4a7147a7cd5923d7a4057e39b</gtr:id><gtr:otherNames>Krystof V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_14666_26_22571657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87C05C1D-1120-459B-9D22-796EED6C86C9</gtr:id><gtr:title>Identification and Characterization of an Irreversible Inhibitor of CDK2.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc3b9f47bd0a4a8300e0993ab69f77f9"><gtr:id>cc3b9f47bd0a4a8300e0993ab69f77f9</gtr:id><gtr:otherNames>Anscombe E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>56d84fc8561c27.50989613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE18F04B-919A-428B-B4F8-AC3166A5A5FA</gtr:id><gtr:title>Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e04d42bdefacfccfc2f59d9ff47b998c"><gtr:id>e04d42bdefacfccfc2f59d9ff47b998c</gtr:id><gtr:otherNames>Hole AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>pm_14666_26_23252711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C08B8374-E1B3-4EF1-A773-543826C2DD8F</gtr:id><gtr:title>8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8839114230b49985244ce99dba391282"><gtr:id>8839114230b49985244ce99dba391282</gtr:id><gtr:otherNames>Carbain B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>545a32e9f39b73.82161366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28E9745E-19CB-4DF2-A0D1-C9A9B8D117B8</gtr:id><gtr:title>The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f8e48a2e79aa7248cba2f4f3f00586"><gtr:id>79f8e48a2e79aa7248cba2f4f3f00586</gtr:id><gtr:otherNames>Baumli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>pm_14666_26_22959624</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901526</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>